Ahorra 5 meses con 1 año de Premium al 35% dto ¡Lo quiero!
2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali
  • 19/02/2020
  • 7
  • 0
  • 0

2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali

Audio no disponible. Inténtalo más tarde.
  • Descargar
  • Compartir
  • Me gusta
  • Más
    • Escuchar en popup
    • Denunciar Contenido
Preparando para la descarga

Preparando audio para descarga.

Escucha patrocinada. El audio empezará en pocos segundos...

Escucha sin anuncios y sin esperas con iVoox Premium

Pruébalo Gratis

X

Descripción de 2.38 KEYNOTE-048, Academic Currency, & Trials in Low/Mid-Income Countries with Dr. Bishal Gyawali

We start this episode by diving deep into KEYNOTE-048, the randomized, open-label, phase 3 study of pembrolizumab alone or with chemotherapy v.s. cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). We transition from there to a continued discussion on careerism in academia and how the motivation behind publishing papers should always stem from the drive to disseminate information, not from the drive to advance your own career. We end the episode with an interview with Dr. Bishal Gyawali of Queen's University in Kingston, Canada on his recent paper out in Nature Cancer on global oncology. Specifically, Dr. Gyawali addresses the need for conducting cancer clinical trials in low- and middle-income countries. KEYNOTE-048: doi.org/10.1016/S0140-6736(19)32591-7 Opportunities for Cancer Clinical Trials in LMIC: doi.org/10.1038/s43018-020-0030-x Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

Mostrar Ocultar

Comentarios

Por decisión del propietario, no se aceptan comentarios anónimos. Registrate para comentarlo.

Más de Ciencia y naturaleza

VER TODOS